Geneva Partners’s AstraZeneca AZN Stock Holding History

Geneva Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,350	Closed	-$1.91M	–	67
2023 Q2	$1.91M	Buy	13,350 +4,985	+60%	+$733K	1.25%	29
2023 Q1	$1.16M	Sell	8,365 -90	-1%	-$12.1K	0.99%	35
2022 Q4	$1.15M	Sell	8,455 -2,632	-24%	-$330K	1.08%	30
2022 Q3	$1.22M	Sell	11,087 -13,436	-55%	-$1.7M	1.39%	24
2022 Q2	$3.24M	Buy	+24,523	New	+$3.22M	3.19%	14

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geneva Partners's AZN Position: Q3 2023 in Review

Geneva Partners sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 13,350 shares — an estimated $1.91M sold.

Geneva Partners first reported a position in AZN in Q2 2022 and held it in 5 quarters. The position peaked at $3.24M in Q2 2022. 1,075 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Geneva Partners reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Geneva Partners sold 13,350 AstraZeneca shares in Q3 2023, an estimated $1.91M.
Geneva Partners first reported a position in AstraZeneca in Q2 2022 and held it in 5 quarters.
Geneva Partners's AstraZeneca position peaked at $3.24M in Q2 2022.
1,075 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Geneva Partners's 13F filing for Q3 2023, filed 25 Oct 2023.